These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

254 related articles for article (PubMed ID: 20472343)

  • 1. Prognostic factors in stereotactic body radiotherapy for non-small-cell lung cancer.
    Matsuo Y; Shibuya K; Nagata Y; Takayama K; Norihisa Y; Mizowaki T; Narabayashi M; Sakanaka K; Hiraoka M
    Int J Radiat Oncol Biol Phys; 2011 Mar; 79(4):1104-11. PubMed ID: 20472343
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Survival and treatment of non-small cell lung cancer stage I-II treated surgically or with stereotactic body radiotherapy: patient and tumor-specific factors affect the prognosis.
    Mokhles S; Nuyttens JJ; Maat AP; Birim Ö; Aerts JG; Bogers AJ; Takkenberg JJ
    Ann Surg Oncol; 2015 Jan; 22(1):316-23. PubMed ID: 24962941
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fibroblast growth factor 2--a predictor of outcome for patients irradiated for stage II-III non-small-cell lung cancer.
    Rades D; Setter C; Dahl O; Schild SE; Noack F
    Int J Radiat Oncol Biol Phys; 2012 Jan; 82(1):442-7. PubMed ID: 20950963
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pleural lavage cytology before and after lung resection in non-small cell lung cancer patients.
    Enatsu S; Yoshida J; Yokose T; Nishimura M; Nishiwaki Y; Shirakusa T; Nagai K
    Ann Thorac Surg; 2006 Jan; 81(1):298-304. PubMed ID: 16368385
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Stereotactic body radiation therapy for early-stage non-small-cell lung cancer: the pattern of failure is distant.
    Bradley JD; El Naqa I; Drzymala RE; Trovo M; Jones G; Denning MD
    Int J Radiat Oncol Biol Phys; 2010 Jul; 77(4):1146-50. PubMed ID: 19800181
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Surgical treatment of primary lung cancer with synchronous brain metastases.
    Billing PS; Miller DL; Allen MS; Deschamps C; Trastek VF; Pairolero PC
    J Thorac Cardiovasc Surg; 2001 Sep; 122(3):548-53. PubMed ID: 11547308
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical Outcomes in Early-stage NSCLC Treated with Stereotactic Body Radiotherapy Versus Surgical Resection.
    Kastelijn EA; El Sharouni SY; Hofman FN; Van Putte BP; Monninkhof EM; Van Vulpen M; Schramel FM
    Anticancer Res; 2015 Oct; 35(10):5607-14. PubMed ID: 26408733
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dose-response for stereotactic body radiotherapy in early-stage non-small-cell lung cancer.
    Olsen JR; Robinson CG; El Naqa I; Creach KM; Drzymala RE; Bloch C; Parikh PJ; Bradley JD
    Int J Radiat Oncol Biol Phys; 2011 Nov; 81(4):e299-303. PubMed ID: 21477948
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Stereotactic Body Radiation Therapy for Non-Small Cell Lung Cancer Tumors Greater Than 5 cm: Safety and Efficacy.
    Woody NM; Stephans KL; Marwaha G; Djemil T; Videtic GM
    Int J Radiat Oncol Biol Phys; 2015 Jun; 92(2):325-31. PubMed ID: 25841625
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Predictive factors for local control in primary and metastatic lung tumours after four to five fraction stereotactic ablative body radiotherapy: a single institution's comprehensive experience.
    Thibault I; Poon I; Yeung L; Erler D; Kim A; Keller B; Lochray F; Jain S; Soliman H; Cheung P
    Clin Oncol (R Coll Radiol); 2014 Nov; 26(11):713-9. PubMed ID: 25085765
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Promising clinical outcome of stereotactic body radiation therapy for patients with inoperable Stage I/II non-small-cell lung cancer.
    Xia T; Li H; Sun Q; Wang Y; Fan N; Yu Y; Li P; Chang JY
    Int J Radiat Oncol Biol Phys; 2006 Sep; 66(1):117-25. PubMed ID: 16765528
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Complications and outcomes after pulmonary resection for cancer in patients 80 to 89 years of age.
    Matsuoka H; Okada M; Sakamoto T; Tsubota N
    Eur J Cardiothorac Surg; 2005 Sep; 28(3):380-3. PubMed ID: 16054820
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dose-volume comparison of proton radiotherapy and stereotactic body radiotherapy for non-small-cell lung cancer.
    Kadoya N; Obata Y; Kato T; Kagiya M; Nakamura T; Tomoda T; Takada A; Takayama K; Fuwa N
    Int J Radiat Oncol Biol Phys; 2011 Mar; 79(4):1225-31. PubMed ID: 20732759
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tumor volume-adapted dosing in stereotactic ablative radiotherapy of lung tumors.
    Trakul N; Chang CN; Harris J; Chapman C; Rao A; Shen J; Quinlan-Davidson S; Filion EJ; Wakelee HA; Colevas AD; Whyte RI; Dieterich S; Maxim PG; Hristov D; Tran P; Le QT; Loo BW; Diehn M
    Int J Radiat Oncol Biol Phys; 2012 Sep; 84(1):231-7. PubMed ID: 22381907
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Size matters: a comparison of T1 and T2 peripheral non-small-cell lung cancers treated with stereotactic body radiation therapy (SBRT).
    Dunlap NE; Larner JM; Read PW; Kozower BD; Lau CL; Sheng K; Jones DR
    J Thorac Cardiovasc Surg; 2010 Sep; 140(3):583-9. PubMed ID: 20478576
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic significance of subcarinal station in non-small cell lung cancer with T1-3 N2 disease.
    Iwasaki A; Shirakusa T; Miyoshi T; Hamada T; Enatsu S; Maekawa S; Hiratsuka M
    Thorac Cardiovasc Surg; 2006 Feb; 54(1):42-6. PubMed ID: 16485188
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of tumor attachment to the pleura measured by a pretreatment CT image on outcome of stage I NSCLC treated with stereotactic body radiotherapy.
    Yamamoto T; Kadoya N; Shirata Y; Koto M; Sato K; Matsushita H; Sugawara T; Umezawa R; Kubozono M; Ishikawa Y; Kozumi M; Takahashi N; Ito K; Katagiri Y; Takeda K; Jingu K
    Radiat Oncol; 2015 Feb; 10():35. PubMed ID: 25886315
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Preliminary report of late recurrences, at 5 years or more, after stereotactic body radiation therapy for non-small cell lung cancer.
    Matsuo Y; Shibuya K; Nagata Y; Norihisa Y; Narabayashi M; Sakanaka K; Ueki N; Mizowaki T; Hiraoka M
    J Thorac Oncol; 2012 Feb; 7(2):453-6. PubMed ID: 22252562
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of subsets of patients with favorable prognosis after recurrence in completely resected non-small cell lung cancer.
    Sonobe M; Yamada T; Sato M; Menju T; Aoyama A; Sato T; Chen F; Omasa M; Bando T; Date H
    Ann Surg Oncol; 2014 Aug; 21(8):2546-54. PubMed ID: 24633668
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effect of non-small cell lung cancer histology on survival as measured by the graded prognostic assessment in patients with brain metastases treated by hypofractionated stereotactic radiotherapy.
    Ma LH; Li G; Zhang HW; Wang ZY; Dang J; Zhang S; Yao L
    Radiat Oncol; 2016 Jul; 11():92. PubMed ID: 27411944
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.